Mounjaro Cuts Heart Attack Risk 33% in Type 2 Diabetes Patients, Study Finds
Updated
Updated · Healthline · Aug 11
Mounjaro Cuts Heart Attack Risk 33% in Type 2 Diabetes Patients, Study Finds
3 articles · Updated · Healthline · Aug 11
Summary
A 52,971-patient insurance-data study found tirzepatide users had a 2.9% one-year risk of major cardiovascular events versus 4.4% for sitagliptin in people with type 2 diabetes and established heart disease.
Researchers estimated 1 major cardiovascular event could be prevented for every 70 people starting tirzepatide, with no meaningful difference seen for ischemic stroke.
The analysis also linked tirzepatide to fewer infection hospitalizations, fewer infection deaths, and lower all-cause mortality during follow-up.
Mounjaro is approved for type 2 diabetes, not cardiac risk reduction, and researchers said the observational design and relatively short follow-up mean the findings still need confirmation.